Huifang Li

2660 Oak Street
Vancouver, BC V6H3Z6, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors.

Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors.

Journal: Cells

Published: August 18, 2022

Improved Accuracy for Modeling PROTAC-Mediated Ternary Complex Formation and Targeted Protein Degradation via New In Silico Methodologies.

Improved Accuracy for Modeling PROTAC-Mediated Ternary Complex Formation and Targeted Protein Degradation via New In Silico Methodologies.

Journal: Journal of chemical information and modeling

Published: September 24, 2020

Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.

Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.

Journal: European journal of medicinal chemistry

Published: May 02, 2018

Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.

Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.

Journal: Cancer letters

Published: April 03, 2018

Discovery, optimization and biological evaluation for novel c-Met kinase inhibitors.

Discovery, optimization and biological evaluation for novel c-Met kinase inhibitors.

Journal: European journal of medicinal chemistry

Published: September 23, 2017

Best Practices of Computer-Aided Drug Discovery: Lessons Learned from the Development of a Preclinical Candidate for Prostate Cancer with a New Mechanism of Action.

Best Practices of Computer-Aided Drug Discovery: Lessons Learned from the Development of a Preclinical Candidate for Prostate Cancer with a New Mechanism of Action.

Journal: Journal of chemical information and modeling

Published: April 26, 2017

Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions.

Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions.

Journal: Molecular cancer therapeutics

Published: March 21, 2017

Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

Journal: The Journal of biological chemistry

Published: March 12, 2017

Correction to Discovery of Small-Molecule Inhibitors Selectively Targeting the DNA-Binding Domain of the Human Androgen Receptor.

Correction to Discovery of Small-Molecule Inhibitors Selectively Targeting the DNA-Binding Domain of the Human Androgen Receptor.

Journal: Journal of medicinal chemistry

Published: January 25, 2017

Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

Journal: The Journal of biological chemistry

Published: October 27, 2015

Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

Journal: The Journal of biological chemistry

Published: August 03, 2014

Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.

Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.

Journal: Journal of medicinal chemistry

Published: July 26, 2014

Showing 1-12 of 16

Last Updated: 09/26/2026